Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider
- 346 Downloads
This analysis investigated the persistence of teriparatide for treatment of osteoporosis in 829 patients according to gender and health care provider treated with teriparatide. This study showed that female patients were less persistent than males and those patients treated in the practices of orthopedic surgeons were more treatment persistent than patients treated in general practitioner (GP) practices.
The optimal persistency of teriparatide (TPTD) is of the upmost importance to ensure fracture risk reduction and pain relief. Data reporting on gender-specific or health care provider-dependent differences on health care provider-dependent persistence is currently lacking.
We analyzed a large dataset extracted from the Disease Analyzer database (IMS Health, Germany). Out of a dataset of 15 million patients, we identified patients with osteoporosis who received first-time teriparatide prescriptions from January 2005 to December 2012.
All 829 patients (677 females and 152 males) were included in the study. The patients were treated by 214 general practitioners (GPs) and 143 orthopedic surgeons. After 18 months of follow-up, 39.5 % of the female and 34 % of the male patients discontinued their treatment (p = 0.0308). We found a significant difference in the discontinuation rate of patients treated by orthopedic surgeons (35.0 %) compared to patients treated by GPs (44.2 %) (p = 0.0445). Additionally, at the end of the 18 months of follow up, 39.4 % of female and 47.8 % of male patients were still on treatment. We found a highly significant decreased risk for treatment discontinuation in patients with fractures prior to treatment initiation compared to those without such fractures (hazard ratio (HR) 0.77; 95 % confidence interval (CI) 0.66–0.90). There was a significantly increased risk of treatment discontinuation for female patients (HR 1.38; 95 % CI 1.10–1.74) compared to male patients.
In conclusion, female patients presented higher discontinuation rates of TPTD compared to males. Patients treated in the practices of orthopedic surgeons were more persistent than patients treated in GP practices. TPTD persistence in patients with osteoporosis is higher than with antiresorptives but is still suboptimal and needs to be improved to ensure fracture risk reductions comparable to randomized controlled trial (RCT) results.
KeywordsCompliance Fracture Osteoporosis Persistence Teriparatide
Conflicts of interest
PH received a speaker’s fee and educational and research funding from Amgen, Astra Zeneca, Elli Lilly, MSD, Novartis, Pfizer, P&G, and Roche. IK, AK, and USA have no conflicts of interest to declare. KK is the employer of IMS with no further conflicts of interest.
- 1.Pfeilschifter J, German Specialist Organisation for O (2006) DVO-guideline for prevention, diagnosis, and therapy of osteoporosis for women after menopause, for men after age 60 executive summary guidelines. Exp Clin Endocrinol Diab: Off J German Soc Endocrinol German Diab Assoc 114(10):611–22Google Scholar
- 2.Hadji P, Klein S, Gothe H, Haussler B, Kless T, Schmidt T et al (2013) The epidemiology of osteoporosis—Bone Evaluation Study (BEST): an analysis of routine health insurance data. Deutsches Arzteblatt Int 110(4):52–7Google Scholar
- 5.Hadji P, Blettner M, Harbeck N, Jackisch C, Luck HJ, Windemuth-Kieselbach C et al (2013) The Patient’s Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 24(6):1505–12CrossRefGoogle Scholar
- 6.Hadji P, Jackisch C, Bolten W, Blettner M, Hindenburg HJ, Klein P et al (2014) Compliance and arthralgia in clinical therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 25(2):372–7CrossRefGoogle Scholar
- 8.Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T (2012) GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int: J Established Result Cooperation between Eur Found Osteoporos Natl Osteoporos Found USA 23(1):223–31CrossRefGoogle Scholar
- 16.Foster SA, Foley KA, Meadows ES, Johnston JA, Wang SS, Pohl GM (2011) Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance. Osteoporos Int: J Established Result Cooperation between Eur Found Osteoporos Natl Osteoporos Found USA 22(2):551–7CrossRefGoogle Scholar
- 17.Adachi JD, Hanley DA, Lorraine JK, Yu M (2007) Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study. Clin Ther 29(9):2055–67PubMedCrossRefGoogle Scholar
- 22.Kyvernitakis I, Ziller V, Hars O, Bauer M, Kalder M, Hadji P (2014) Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer. Climacteric: J Int Menopause Soc 17(3):252–9Google Scholar